{"pmid":32443163,"title":"Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta.","text":["Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta.","The pharmacological and immunological properties of interferons, especially those of interferon beta, and the corresponding treatment strategies are described, and the results of studies with different interferons in coronavirus infections are analysed. Furthermore, the data obtained with high-dosed native interferon beta in life-threatening acute viral diseases as well as the results of clinical pilot studies with high-dosed recombinant interferon beta-1a are provided because they serve as the rationale for the proposed therapeutic regimen to be applied in acute viral infections. This regimen differs from those approved for treatment of multiple sclerosis and consists of interferon beta-1a administered as a 24 hour intravenous infusion at a daily dose of up to 90 microg for 3-5 consecutive days. Since under this regimen transient severe side effects can occur, it is analysed which patients are suitable for this kind of treatment in general and if patients with severe coronavirus infections could also be treated accordingly.","Drug Res (Stuttg)","Brzoska, Josef","von Eick, Harald","Hundgen, Manfred","32443163"],"abstract":["The pharmacological and immunological properties of interferons, especially those of interferon beta, and the corresponding treatment strategies are described, and the results of studies with different interferons in coronavirus infections are analysed. Furthermore, the data obtained with high-dosed native interferon beta in life-threatening acute viral diseases as well as the results of clinical pilot studies with high-dosed recombinant interferon beta-1a are provided because they serve as the rationale for the proposed therapeutic regimen to be applied in acute viral infections. This regimen differs from those approved for treatment of multiple sclerosis and consists of interferon beta-1a administered as a 24 hour intravenous infusion at a daily dose of up to 90 microg for 3-5 consecutive days. Since under this regimen transient severe side effects can occur, it is analysed which patients are suitable for this kind of treatment in general and if patients with severe coronavirus infections could also be treated accordingly."],"journal":"Drug Res (Stuttg)","authors":["Brzoska, Josef","von Eick, Harald","Hundgen, Manfred"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32443163","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1055/a-1170-4395","topics":["Treatment"],"weight":1,"_version_":1667523504887562240,"score":9.490897,"similar":[{"pmid":32496210,"title":"Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-alpha1b for COVID-19.","text":["Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-alpha1b for COVID-19.","Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 was highly infectious and difficult to control. A dual-combination of ribavirin and interferon-alpha has been the widely used regimen for the treatment of this disease in China. However, due to the varying results of treatment with these drugs, a novel antiviral combination therapy is urgently needed. This case reports the usage of lopinavir/ritonavir-based combination antiviral regimen for a patient with SARS-CoV-2 infection.","Antivir Ther","Xie, Xiangyang","Jiang, Yuanliang","Zeng, Yuan","Liu, Hui","32496210"],"abstract":["Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 was highly infectious and difficult to control. A dual-combination of ribavirin and interferon-alpha has been the widely used regimen for the treatment of this disease in China. However, due to the varying results of treatment with these drugs, a novel antiviral combination therapy is urgently needed. This case reports the usage of lopinavir/ritonavir-based combination antiviral regimen for a patient with SARS-CoV-2 infection."],"journal":"Antivir Ther","authors":["Xie, Xiangyang","Jiang, Yuanliang","Zeng, Yuan","Liu, Hui"],"date":"2020-06-05T11:00:00Z","year":2020,"_id":"32496210","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.3851/IMP3362","locations":["Wuhan","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1668712823933370368,"score":246.191},{"pmid":32426209,"pmcid":"PMC7228888","title":"Are Type 1 Interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?","text":["Are Type 1 Interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?","Background: : The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned respiratory insufficiency and death. At first, it was thought that the patients who use immunmodulator therapy could be even at higher risks of disease complications. However, it has been also speculated about that using immunmodulators could be an advantage for the clinical prognosis. Therefore, several immunmodulators are currently being tested as potential treatment for COVID-19. Methods: : In this paper we report on a patient that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19. Results: : Despite using immunmodulator, the symptoms of the patient at hospitalization were mild and he did not show elevated D-dimer, and there was no lymphopenia. He was discharged to home-quarantine with no symptoms. Discussion: : This report supports the idea of using type 1 interferon in the treatment could be effective in COVID-19 affected patients.","Mult Scler Relat Disord","Gemcioglu, Emin","Davutoglu, Mehmet","Ozdemir, Ese Ece","Erden, Abdulsamet","32426209"],"abstract":["Background: : The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned respiratory insufficiency and death. At first, it was thought that the patients who use immunmodulator therapy could be even at higher risks of disease complications. However, it has been also speculated about that using immunmodulators could be an advantage for the clinical prognosis. Therefore, several immunmodulators are currently being tested as potential treatment for COVID-19. Methods: : In this paper we report on a patient that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19. Results: : Despite using immunmodulator, the symptoms of the patient at hospitalization were mild and he did not show elevated D-dimer, and there was no lymphopenia. He was discharged to home-quarantine with no symptoms. Discussion: : This report supports the idea of using type 1 interferon in the treatment could be effective in COVID-19 affected patients."],"journal":"Mult Scler Relat Disord","authors":["Gemcioglu, Emin","Davutoglu, Mehmet","Ozdemir, Ese Ece","Erden, Abdulsamet"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426209","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.msard.2020.102196","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1667252837684346880,"score":240.61368},{"pmid":32480326,"title":"Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?","text":["Are type 1 interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19?","BACKGROUND: The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned respiratory insufficiency and death. At first, it was thought that the patients who use immunmodulator therapy could be even at higher risks of disease complications. However, it has been also speculated about that using immunmodulators could be an advantage for the clinical prognosis. Therefore, several immunmodulators are currently being tested as potential treatment for COVID-19. METHODS: In this paper we report on a patient that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19. RESULTS: Despite using immunmodulator, the symptoms of the patient at hospitalization were mild and he did not show elevated D-dimer, and there was no lymphopenia. He was discharged to home-quarantine with no symptoms. DISCUSSION: This report supports the idea of using type 1 interferon in the treatment could be effective in COVID-19 affected patients.","Mult Scler Relat Disord","Gemcioglu, Emin","Davutoglu, Mehmet","Ozdemir, Ese Ece","Erden, Abdulsamet","32480326"],"abstract":["BACKGROUND: The Coronavirus (COVID-19), (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) has been spreading worldwide since its first identification in China. It has been speculated that patients with comorbidities and elderly patients could be at high risk for the pandemic reasoned respiratory insufficiency and death. At first, it was thought that the patients who use immunmodulator therapy could be even at higher risks of disease complications. However, it has been also speculated about that using immunmodulators could be an advantage for the clinical prognosis. Therefore, several immunmodulators are currently being tested as potential treatment for COVID-19. METHODS: In this paper we report on a patient that has been treated with type 1 interferon for multiple sclerosis who developed COVID-19. RESULTS: Despite using immunmodulator, the symptoms of the patient at hospitalization were mild and he did not show elevated D-dimer, and there was no lymphopenia. He was discharged to home-quarantine with no symptoms. DISCUSSION: This report supports the idea of using type 1 interferon in the treatment could be effective in COVID-19 affected patients."],"journal":"Mult Scler Relat Disord","authors":["Gemcioglu, Emin","Davutoglu, Mehmet","Ozdemir, Ese Ece","Erden, Abdulsamet"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32480326","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.msard.2020.102196","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1668437834978033664,"score":240.61368},{"pmid":32360182,"title":"Antiviral activities of type I interferons to SARS-CoV-2 infection.","text":["Antiviral activities of type I interferons to SARS-CoV-2 infection.","There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons alpha and beta (IFNalpha/beta). Treatment with IFN-alpha or IFN-beta at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-alpha and IFN-beta treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19.","Antiviral Res","Mantlo, Emily","Bukreyeva, Natalya","Maruyama, Junki","Paessler, Slobodan","Huang, Cheng","32360182"],"abstract":["There is an urgent need to identify antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2 to recombinant human interferons alpha and beta (IFNalpha/beta). Treatment with IFN-alpha or IFN-beta at a concentration of 50 international units (IU) per milliliter reduces viral titers by 3.4 log or over 4 log, respectively, in Vero cells. The EC50 of IFN-alpha and IFN-beta treatment is 1.35 IU/ml and 0.76 IU/ml, respectively, in Vero cells. These results suggest that SARS-CoV-2 is more sensitive than many other human pathogenic viruses, including SARS-CoV. Overall, our results demonstrate the potential efficacy of human Type I IFN in suppressing SARS-CoV-2 infection, a finding which could inform future treatment options for COVID-19."],"journal":"Antiviral Res","authors":["Mantlo, Emily","Bukreyeva, Natalya","Maruyama, Junki","Paessler, Slobodan","Huang, Cheng"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360182","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.antiviral.2020.104811","keywords":["antiviral therapy","covid-19","innate immune","interferon","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495505137667,"score":231.72104},{"pmid":32275914,"pmcid":"PMC7138382","title":"Type 1 interferons as a potential treatment against COVID-19.","text":["Type 1 interferons as a potential treatment against COVID-19.","Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19.","Antiviral Res","Sallard, Erwan","Lescure, Francois-Xavier","Yazdanpanah, Yazdan","Mentre, France","Peiffer-Smadja, Nathan","32275914"],"abstract":["Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19."],"journal":"Antiviral Res","authors":["Sallard, Erwan","Lescure, Francois-Xavier","Yazdanpanah, Yazdan","Mentre, France","Peiffer-Smadja, Nathan"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275914","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.antiviral.2020.104791","keywords":["covid-19","interferon","sars-cov-2"],"topics":["Treatment"],"weight":1,"_version_":1666138491668398081,"score":226.38762}]}